{
    "output": [
        [
            "Eiger BioPharmaceuticals, Inc.",
            "COMP",
            "Announce",
            "Appointment of David Apelian",
            "PERSON"
        ],
        [
            "David Apelian",
            "PERSON",
            "Participates_In",
            "Eiger BioPharmaceuticals, Inc.",
            "COMP"
        ],
        [
            "David Apelian",
            "PERSON",
            "Control",
            "Clinical Development and Regulatory Experience",
            "CONCEPT"
        ],
        [
            "Eiger BioPharmaceuticals, Inc.",
            "COMP",
            "Operate_In",
            "Rare Diseases Sector",
            "SECTOR"
        ],
        [
            "David Apelian",
            "PERSON",
            "Raise",
            "Great Value",
            "CONCEPT"
        ],
        [
            "David Apelian",
            "PERSON",
            "Was",
            "Executive VP and Chief Medical Officer of Achillion Pharmaceuticals, Inc.",
            "COMP"
        ],
        [
            "Achillion Pharmaceuticals, Inc.",
            "COMP",
            "Secure",
            "$225 Million Equity Investment",
            "FIN_INSTRUMENT"
        ],
        [
            "David Apelian",
            "PERSON",
            "Lead",
            "Rare Disease Development Program",
            "CONCEPT"
        ],
        [
            "David Apelian",
            "PERSON",
            "Completed",
            "Residency Training in Pediatrics",
            "CONCEPT"
        ],
        [
            "David Apelian",
            "PERSON",
            "Received",
            "MD from University of Medicine and Dentistry of New Jersey",
            "ORG"
        ],
        [
            "David Apelian",
            "PERSON",
            "Earned",
            "BA in Biochemistry from Rutgers University",
            "GPE"
        ]
    ]
}